AN2 Therapeutics, Inc.
ANTX
$1.07
-$0.06-5.31%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.35M | -51.32M | -60.70M | -64.66M | -66.03M |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.37M | 5.06M | 4.77M | 5.13M | 5.25M |
| Change in Net Operating Assets | -2.30M | -3.00M | -5.13M | -1.32M | 1.49M |
| Cash from Operations | -42.29M | -49.26M | -61.05M | -60.85M | -59.29M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 37.49M | 54.59M | 61.89M | -19.29M | -27.88M |
| Cash from Investing | 37.49M | 54.59M | 61.89M | -19.29M | -27.88M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 88.00K | 372.00K | 372.00K | 66.42M | 85.47M |
| Repurchase of Common Stock | -- | -- | -321.00K | -321.00K | -321.00K |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 88.00K | 372.00K | 51.00K | 66.09M | 85.14M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4.71M | 5.70M | 888.00K | -14.04M | -2.02M |